Expanding Access to CAR-T Therapy Operational Models and Best Practices Across the Oncology Care Continuum

Prepared by Kashif Ali, MD, and NCODA for Legend Biotech | September 2026

Is CAR-T Delivery Ready to Scale Beyond the Academic Medical Center?

The landscape for chimeric antigen receptor T-cell (CAR-T) therapy is evolving, with growing use in earlier lines of treatment, expanding outpatient administration, and a widening range of practice settings taking on delivery. But translating these advances into everyday practice can bring real operational, logistical, and coordination challenges.

This white paper, Expanding Access to CAR-T Therapy: Operational Models and Best Practices Across the Oncology Care Continuum, brings together perspectives from physicians, advanced practice providers, pharmacists, nurse coordinators, administrators, and operational leaders across academic medical centers, community oncology practices, outpatient CAR-T programs, and rural referral networks to examine how organizations are expanding access to CAR-T therapy and what it takes to build sustainable, patient-centered programs.

Read the white paper to explore:

• Four distinct CAR-T practice archetypes — formal referral partnerships, emerging referral networks, fully outpatient programs, and rural/geographically isolated referral models — and what each reveals about scalable delivery
• Why the greatest barriers to CAR-T access are increasingly operational rather than clinical
• How multidisciplinary collaboration, standardized SOPs, and embedded pharmacy support help practices safely expand outpatient CAR-T delivery
• What mature community–academic referral partnerships can teach emerging programs about coordinated, shared care
• How rural and geographically isolated cancer centers remain essential partners in the CAR-T journey, even when they don’t administer therapy locally
• Five foundational principles for sustainable, safe, and patient-centered CAR-T delivery, regardless of practice setting

See how oncology teams across the care continuum are navigating the shift from specialized therapy to coordinated, community-connected CAR-T care.

READ WHITEPAPER

References

1. Perez A, Al Sagheer T, Nahas GR, Linhares YPL. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community-based centers. Front Immunol. 2024;15:1412002. Published 2024 May 8. doi:10.3389/fimmu.2024.1412002
2. Dabas P, Danda A. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. Med Oncol. 2023;40(9):275. Published 2023 Aug 22. doi:10.1007/s12032-023-02146-y
3. Epperla N, Kumar A, Abutalib SA, et al. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B-Cell Lymphoma. Transplant Cell Ther. 2023;29(9):548-555. doi:10.1016/j.jtct.2023.06.012
4. Oluwole OO, Dholaria B, Knight TE, et al. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapies. Transplant Cell Ther. 2024;30(2):131-142. doi:10.1016/j.jtct.2023.11.008
5. Gatwood K, Mahmoudjafari Z, Baer B, et al. Outpatient CAR-T Therapy as Standard of Care: Current Perspectives and Considerations. Clin Hematol Int. 2024;6(2):11-20. Published 2024 Apr 9. doi:10.46989/001c.115793
6. U.S. Food and Drug Administration. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor T Cell Immunotherapies. U.S. Food and Drug Administration, 2025, www.fda.gov. Accessed 2026.
7. Simmons GL, Cross S, Pittos EC. Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice. Front Oncol. 2026;16:1712533. Published 2026 Feb 16. doi:10.3389/fonc.2026.1712533
8. Furqan F, Bhatlapenumarthi V, Dhakal B, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024;8(16):4320-4329. doi:10.1182/bloodadvances.2024013239
9. Patel AR, Hasegawa K, Pandya S, et al. Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis. J Manag Care Spec Pharm. 2025;31(11):1110-1122. doi:10.18553/jmcp.2025.31.11.1110